Abstract
Pembrolizumab targets the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway across a range of tumor types with varying degrees of PD-L1 expression. The phase III KEYNOTE-522 and KEYNOTE-355 trials evaluated the addition of pembrolizumab to standard chemotherapy in patients with early-stage and locally advanced or metastatic triple-negative breast cancer (TNBC), respectively 1, 2. Updated findings provide insights on the optimal role of pembrolizumab across TNBC treatment settings.